ÂÜÀòÂÒÂ×

Matvey Lukashev, PhD, has over 30 years of research experience in academia, industry, and non-profit biotech settings. Most recently, Dr. Lukashev served as Vice-President, Translational Sciences at the ALS Therapy Development Institute where he built and led a new translational research and drug discovery function encompassing patient genomics, stem cell biology, genome editing and phenotypic screening for biomarker, target and drug discovery in amyotrophic lateral sclerosis.

Prior to joining the ALS Therapy Development Institute, Dr. Lukashev held positions of increasing responsibility at Biogen, where he received the Biogen Idec Outstanding Achievement Award for his leadership of translational studies supporting clinical development of Tecfidera®. Dr. Lukashev obtained his doctorate in Cell Biology from the USSR Academy of Medical Sciences and received postdoctoral training at John Hopkins University and the University of California, San Francisco.